Timing of BRCA1/BRCA2 genetic testing in women with ovarian cancer

被引:16
作者
Daniels, Molly S. [1 ]
Urbauer, Diana L. [2 ]
Stanley, Jennifer L. [1 ]
Johnson, Kristin G. [3 ]
Lu, Karen H. [1 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Gynecol Oncol, Houston, TX 77230 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Quantitat Sci, Houston, TX 77230 USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Nursing, Houston, TX 77230 USA
关键词
BRCA1; BRCA2; genetic testing; ovarian cancer; cancer recurrence; NONPOLYPOSIS COLORECTAL-CANCER; BRCA2; MUTATIONS; DNA-REPAIR; SURVIVAL; SUSCEPTIBILITY; PREVALENCE; POLYMERASE; INHIBITORS; CARCINOMA; FEATURES;
D O I
10.1097/GIM.0b013e3181ab2295
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Purpose: To determine when, in reference to the course of their treatment. women with ovarian cancer are seen for genetic Counseling. as well as to determine what factors influence this timing. Methods: Single institution retrospective chart review of patients with ovarian cancer Who Underwent BRCA1/BRCA2 genetic testing. Results: Thirty-three percent of our sample (n = 100) were seen for genetic counseling after ovarian cancer recurrence. In four cases, genetic test results were disclosed to next of kin. Thirty percent of women seen for genetic counseling after recurrence received their initial treatment elsewhere. Women with a history of breast cancer were significantly more likely to be seen for genetic counseling at an earlier phase of their treatment than women with no history of breast cancer. Conclusion: We found that one third of patients with ovarian cancer who underwent genetic testing were seen for initial genetic counseling after disease recurrence. In some cases, genetic counseling took place during the end of life care. with genetic test results disclosed to next of kin. Given the poor prognosis of women with recurrent ovarian cancer, we advocate providing genetic Counseling at the time of initial ovarian cancer treatment both in comprehensive cancer centers and in community oncology settings. Genet Med 2009:11(9):624-628.
引用
收藏
页码:624 / 628
页数:5
相关论文
共 26 条
  • [1] [Anonymous], NCCN CLIN PRACT GUID
  • [2] [Anonymous], 2008, Cancer Facts Figures 2008
  • [3] Effect of BRCA mutations on the length of survival in epithelial ovarian tumors
    Ben David, Y
    Chetrit, A
    Hirsh-Yechezkel, G
    Friedman, E
    Beck, BD
    Beller, U
    Ben-Baruch, G
    Fishman, A
    Levavi, H
    Lubin, F
    Menczer, J
    Piura, B
    Struewing, JP
    Modan, B
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (02) : 463 - 466
  • [4] Clinicopathologic features of BRCA-linked and sporadic ovarian cancer
    Boyd, J
    Sonoda, Y
    Federici, MG
    Bogomolniy, F
    Rhei, E
    Maresco, DL
    Saigo, PE
    Almadrones, LA
    Barakat, RR
    Brown, CL
    Chi, DS
    Curtin, JP
    Poynor, EA
    Hoskins, WJ
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 283 (17): : 2260 - 2265
  • [5] Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
    Bryant, HE
    Schultz, N
    Thomas, HD
    Parker, KM
    Flower, D
    Lopez, E
    Kyle, S
    Meuth, M
    Curtin, NJ
    Helleday, T
    [J]. NATURE, 2005, 434 (7035) : 913 - 917
  • [6] Improved survival in women with BRCA-associated ovarian carcinoma
    Cass, I
    Baldwin, RL
    Varkey, T
    Moslehi, R
    Narod, SA
    Karlan, BY
    [J]. CANCER, 2003, 97 (09) : 2187 - 2195
  • [7] Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer:: The national Israeli study of ovarian cancer
    Chetrit, Angela
    Hirsh-Yechezkel, Galit
    Ben-David, Yehuda
    Lubin, Flora
    Friedman, Eitan
    Sadetzki, Siegal
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (01) : 20 - 25
  • [8] Does palliative chemotherapy palliate? Evaluation of expectations, outcomes, and costs in women receiving chemotherapy for advanced ovarian cancer
    Doyle, C
    Crump, M
    Pintilie, M
    Oza, AM
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (05) : 1266 - 1274
  • [9] Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
    Farmer, H
    McCabe, N
    Lord, CJ
    Tutt, ANJ
    Johnson, DA
    Richardson, TB
    Santarosa, M
    Dillon, KJ
    Hickson, I
    Knights, C
    Martin, NMB
    Jackson, SP
    Smith, GCM
    Ashworth, A
    [J]. NATURE, 2005, 434 (7035) : 917 - 921
  • [10] Screening for the Lynch syndrome (Hereditary nonpolyposis colorectal cancer).
    Hampel, H
    Frankel, WL
    Martin, E
    Arnold, M
    Khanduja, K
    Kuebler, P
    Nakagawa, H
    Sotamaa, K
    Prior, TW
    Westman, J
    Panescu, J
    Fix, D
    Lockman, J
    Comeras, I
    de la Chapelle, A
    Ellison, C
    Melvin, S
    Winston, J
    Adeli, A
    Burak, W
    Chadwick, R
    Elkhatib, I
    Hemingway, T
    Jamieson, K
    Johnson, C
    LaJeunesse, J
    Liyanarachchi, S
    Rangel, P
    Soble, D
    Walker, M
    Wise, T
    Zhang, Y
    Schlanger, R
    Aguilar, P
    Hura, D
    Keith, J
    Kerner, B
    Lavalle, G
    Taylor, C
    Vara, T
    Zangmeister, J
    DeVictor, S
    Hines, L
    Lindsey, M
    Madhavan, J
    Padmanabhan, A
    Hamelberg, K
    Niemann, T
    Behrens, BC
    Blair, SC
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (18) : 1851 - 1860